It has been shown that NF-κB and NF-κB-dependent gene products in lymphocytes are up-regulated in TME [21], and the suppression of pro-inflammatory cytokine-mediated signaling pathways by inhibiting cross-talk between tumor cells and inflammatory cells could be a promising therapeutic strategy. Here, NFKB1 is linked to neoplasm.